Evaluating a specific value-based contract requires weighing the potential benefits and risks related to the organization’s capabilities and resources, the financial impact, and credit risk. Physician engagement, transparency and accountability, and performance measurement and improvement all must be in place for a value-based contract to be successfully implemented. We provide the expertise and in-depth understanding of contracting dynamics to ensure success. Value-Based Contracting is what we do!
The report comes days after the HHS alerted the sector to a pro-Russian hacktivist group called Killnet, which recently updated its target list to include hospitals and medical organizations in several countries.
Trade association AHIP said it was “concerned with the potential adverse impact of the rate notice,” especially in light of other recent regulation seeking to claw back overpayments to MA payers.
About 30% of patients selected a new provider in 2021, up from 26% in 2017, according to a new report from Accenture. Gen Zers and millennials were six times more likely to switch providers than older people.
The latest lawsuit focuses on boosted fees that both parties must pay for arbitration to solve billing disputes between providers and payers.
The payer said it expects to pick up 625,000 individual Medicare Advantage members in 2023.
FTC officials said they are putting the market on watch with the enforcement against GoodRx. The digital health company allegedly collected data, including patient medications, and shared it without user consent.
Eduardo Conrado will assume the role from Joseph Impicciche, Ascension’s current chief executive officer.
Care delivered by physicians in health systems costs between 12% and 26% higher than care delivered by independent physicians, according to a study published in JAMA Network.
America’s Health Insurance Plans lobby said the rule seeking to claw back billions of dollars from health insurers is unlawful and fatally flawed.
The decision is a win for drug manufacturers Sanofi, Novo Nordisk and AstraZeneca. The companies sued the HHS after regulators ordered them to stop restricting sales of 340B drugs to contract pharmacies.